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Chronic granulomatous disease (CGD) is a rare primary 
immunodeficiency disease of phagocytic cells, resulting from 
impaired function of one of five essential subunits of the reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
enzyme complex within neutrophils, eosinophils, monocytes and 
macrophages. This enzyme complex mediates intracellular killing 
of phagocytosed micro-organisms. The NADPH oxidase complex is 
composed of membrane-bound glycoproteins gp91phox and p22phox, 
and cytosolic subunits p47phox, p67phox, p40phox and rac. Although 
mutations in genes encoding any one of these protein subunits can 
result in the disease, 70% of cases are due to mutations in the CYBB 
gene causing gp91phox deficiency, which is responsible for X-linked 
CGD.1,2 Autosomal recessive forms of CGD due to mutations in genes 
encoding p47phox, p22phox, p67phox and p40phox have been described.2
Failure to mediate oxidative killing results in susceptibility to 
recurrent life-threatening bacterial and fungal infections and increased 
risk of mycobacterial infections.1 In the past, mortality from CGD 
was exceptionally high, but antibiotic and antifungal prophylaxis and 
therapy, and haematopoietic stem cell transplantation has improved 
outcomes significantly and reduced mortality to 5%.1 The worldwide 
prevalence of CGD is estimated to be 1 in 200 000 - 250 000 live 
births.1 Since 1983, 6 cases in South Africa have been reported in the 
literature, all diagnosed by immunological testing.3 We describe the 
first genetically confirmed case of CGD in this country.
Case report
In June 2010, a 5-year-old boy with a past history of recurrent 
tuberculosis (TB) presented to his paediatrician with left lower lobe 
consolidation, generalised lymphadenopathy and marked failure to 
thrive. Bacterial and mycobacterial cultures were negative and, in 
view of his past history, he was suspected of having drug-resistant 
TB. He had been well up until 15 months of age, when pulmonary 
TB was diagnosed, and he received 6 months of anti-TB medication. 
However, he presented a year later with abdominal TB. He responded 
to a second course of therapy, but at the age of 4 years presented 
with a discharging sinus over the right arm and right axillary 
scrofuloderma. Histological analysis of the skin biopsy confirmed 
the presence of intracellular acid-fast bacilli, although mycobacterial 
cultures were negative. He responded to a third course of anti-TB 
medication. There was no preceding history of severe acute bacterial 
infections.
Upon transfer to Red Cross War Memorial Children’s Hospital, 
clinical evaluation revealed wasting, generalised lymphadenopathy, 
and left lower lobe consolidation on respiratory examination. There 
was tenderness over the thoracic spine but no gibbus formation. 
Although globally weak, no neurological abnormalities were present. 
Chest computed tomography (CT) showed opacification in the left 
lower lobe, multiple bilateral upper lobe parenchymal nodules, a 
contiguous left paravertebral density along thoracic vertebrae 7 - 11, 
erosion of ribs 7 and 8, and partial height loss of corresponding 
thoracic vertebral bodies. A lung biopsy showed granulomatous 
inflammation and septated hyphae with dichotomous branching 
resembling Aspergillus infection. Fungal cultures, however, were 
negative. He was initially commenced on amphotericin B but 
changed to intravenous voriconazole a week later.
The clinical course improved and he was converted to oral 
voriconazole after 3 weeks. However, a month into therapy, he 
developed collapse of thoracic vertebrae 6 - 8 and required spinal 
cord decompression. Culture from the spinal mass confirmed 
Aspergillus fumigatus infection. The myelopathy improved gradually. 
However, 6 months later, mild bilateral lower limb hypertonia 
persisted. Follow-up chest CT showed calcification of the pulmonary 
nodules but persistence of the paravertebral mass and left lower lobe 
consolidation. The patient remains on long-term therapeutic oral 
voriconazole and cotrimoxazole prophylaxis.
Immunological work-up demonstrated evidence of reduced 
neutrophil killing capacity, i.e. a monocyte oxidative reaction of 
14.26% (normal 70 - 100%) and neutrophil oxidative reaction of 
17.44% (normal 95 - 100%), which suggested a diagnosis of CGD. This 
was confirmed on repeat neutrophil burst testing. Immunoglobulin 
concentrations, complement screen and lymphocyte subset analysis 
were relatively normal.
Although there was no reported family history of primary 
immunodeficiencies, 2 maternal uncles and 1 maternal male cousin 
died in infancy of unknown causes that suggested an X-linked 
inheritance pattern (Fig. 1). Sequencing of the CYBB gene on 
peripheral blood samples was completed by the University of 
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Hong Kong;4 13 exon fragments were amplified using HotStarTaq 
Plus PCR system (Qiagen GmbH, Germany). Homology analysis 
of the sequenced data with CYBB genomic DNA was performed 
through the NCBI database (http://www.ncbi.nlm.nih.gov/BLAST) 
and the Ensembl SNPs database (http://www.ensembl.org). Analysis 
of the CYBB gene of the patient revealed a novel insertion-deletion 
mutation in exon 10, while his mother was found to be a heterozygous 
carrier of the mutation (Fig. 2).
Discussion
We describe a patient with CGD and a novel mutation in the CYBB 
gene. If the South African incidence is similar to international 
prevalence, 4 - 5 new cases of CGD should be identified in the 
country per year, which suggests that many children with CGD are 
not being diagnosed, most probably owing to failure to recognise the 
clinical manifestations.
Three mycobacterial infections and invasive aspergillosis in our 
patient is consistent with CGD. Acute bacterial infections with 
Staphylococcus aureus, Burkholderia cepacia, Serratia marcescens and 
Nocardia sp. predominate, while Aspergillus – the most frequently 
associated fungal infection – is the leading cause of morbidity and 
mortality.1,2 Several CGD patients with Bacille-Calmette-Guérin 
(BCG) disease and TB have been described in regions endemic for 
tuberculosis.4 Other CYBB mutations not related to CGD have also 
been associated with X-linked recessive mendelian susceptibility to 
mycobacteria.5 Other primary immunodeficiency diseases (PIDs) 
that cause recurrent mycobacterial infections include X-linked 
hyper-IgM syndrome, severe combined immunodeficiency syndrome 
and deficiencies of the IL-12/23-IFN-γ axis.
Sequencing of the CYBB gene documented a novel insertion-
deletion mutation in exon 10 which resulted in amino acid alterations 
at positions 388 and 389. Over 400 different mutations of the CYBB 
gene have been described.6 While mutational analysis is important 
for definitive diagnosis, it is not routinely available, however, and 
immunological evaluation with neutrophil burst testing is sufficient 
to make a diagnosis and initiate treatment. Prophylactic antibiotic 
therapy with cotrimoxazole has been effective in reducing serious 
bacterial infections, while prophylactic itraconazole has substantially 
decreased the number of Aspergillus infections.1,2 Interferon-gamma 
has also been shown to be a highly effective prophylactic therapy, but 
the cost remains prohibitive in resource-limited settings.1
Improved recognition of CGD and early diagnosis is the cornerstone 
in reducing morbidity and mortality, so that prophylaxis may be 
initiated early, infections may be treated promptly and possibly 
curative haematopoietic stem cell transplantation considered.
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Fig. 1. Pedigree of the family showing the affected patient (■) and carrier 
female (mother), genetically normal male (father) and male deaths in the 
maternal family. (Cyrillic Pedigree Editor Version 2.0.1.0)
Fig. 2. X-CGD molecular diagnosis by PCR-direct sequencing of CYBB gene 
(naming according to Ref. sequence of CYBBbase, http://bioinf.uta.fi/CYBB-
base/). (A) Index patient: X-linked indel mutation in exon 10 - “TGG” dele-
tion and “ATC” insertion at nucleotide position 1178-1180, Asp-Gly (codon 
GAT-GGG) change to Glu-Ser (codon GAA-TCG) at amino acid position 
388-389. c.1178_1180delinsATC, p.DG388_389ES, (B) Mother: Heterozy-
gous mutation, carrier, and (C) Father: genetically normal.
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